From: Evaluating key performance indicators of the process of care in juvenile idiopathic arthritis
KPI | N (%) |
---|---|
Safety KPIs | |
Tuberculosis Screening | |
Number of patients with documentation of a TB test for a biologic start in SCM, Practitioner Claims, NACRS, or Consolidated Laboratory Repository [n = 56], n (%) | 54 (96%) |
SCM [n = 56] | 53 (95%) |
Practitioner Claims [n = 56] | 18 (32%) |
NACRS [n = 56] | 4 (7%) |
Consolidated Laboratory Repository [n = 56] | 5 (9%) |
Number of patients screened for TB within 12 months prior to receiving a first course of therapy using a biologic DMARD [n = 56] | 5 (9%) |
Practitioner Claims [n = 18] | 3 (17%) |
NACRS [n = 4] | 2 (50%) |
Consolidated Laboratory Repository [n = 5] | 0 |
Laboratory monitoring for DMARDs | |
Number of patients on methotrexate and leflunomide with documentation of toxicity monitoring in the Consolidated Laboratory Repository [n = 102] | 102 (100%) |
0–1 month [n = 102] | 60 (59%) |
1–4 months [n = 101] | 85 (84%) |
4–8 months [n = 94] | 85 (90%) |
8–12 months [n = 88] | 77 (88%) |
12–16 months [n = 79] | 70 (89%) |
16–20 months [n = 68] | 53 (78%) |
20–24 months [n = 55] | 42 (76%) |
Number of patients who received methotrexate and leflunomide and monitored for toxicity by clinical laboratory methods in the Consolidated Laboratory Repository during every eligible interval [n = 102] | 29 (28%) |
Number of patients on methotrexate or leflunomide with mention of laboratory tests orderedb in SCM at every eligible visit [n = 99]a | 22 (22%) |
Number of patients on methotrexate or leflunomide with mention of laboratory test resultsc in SCM at every eligible visit [n = 99]a | 33 (33%) |